[go: up one dir, main page]

MA38583B1 - Dérivés de dolastatine 10 et d'auristatines - Google Patents

Dérivés de dolastatine 10 et d'auristatines

Info

Publication number
MA38583B1
MA38583B1 MA38583A MA38583A MA38583B1 MA 38583 B1 MA38583 B1 MA 38583B1 MA 38583 A MA38583 A MA 38583A MA 38583 A MA38583 A MA 38583A MA 38583 B1 MA38583 B1 MA 38583B1
Authority
MA
Morocco
Prior art keywords
auristatines
dolastatin
derivatives
compound
relates
Prior art date
Application number
MA38583A
Other languages
English (en)
Other versions
MA38583A1 (fr
Inventor
Michel Perez
Ian Rilatt
Marie Lamothe
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA38583A1 publication Critical patent/MA38583A1/fr
Publication of MA38583B1 publication Critical patent/MA38583B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un composé de formule suivante (i): où : r
MA38583A 2013-04-25 2014-04-25 Dérivés de dolastatine 10 et d'auristatines MA38583B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1353793A FR3005051A1 (fr) 2013-04-25 2013-04-25 Derives de la dolastatine 10 et d'auristatines
PCT/EP2014/058427 WO2014174064A1 (fr) 2013-04-25 2014-04-25 Dérivés de dolastatine 10 et d'auristatines

Publications (2)

Publication Number Publication Date
MA38583A1 MA38583A1 (fr) 2018-07-31
MA38583B1 true MA38583B1 (fr) 2018-11-30

Family

ID=48782433

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38583A MA38583B1 (fr) 2013-04-25 2014-04-25 Dérivés de dolastatine 10 et d'auristatines

Country Status (32)

Country Link
US (7) US20160083420A1 (fr)
EP (4) EP2989088B1 (fr)
JP (3) JP6606489B2 (fr)
KR (4) KR102389167B1 (fr)
CN (3) CN105377834B (fr)
AU (3) AU2014259429A1 (fr)
BR (3) BR112015026478A2 (fr)
CA (4) CA2910178A1 (fr)
CY (2) CY1119677T1 (fr)
DK (3) DK3388427T3 (fr)
ES (3) ES2693368T3 (fr)
FR (1) FR3005051A1 (fr)
HK (2) HK1215580A1 (fr)
HR (2) HRP20171977T1 (fr)
HU (3) HUE035180T2 (fr)
IL (1) IL242184A (fr)
LT (2) LT2989088T (fr)
MA (1) MA38583B1 (fr)
MX (3) MX2015014831A (fr)
MY (1) MY177702A (fr)
NO (1) NO2989088T3 (fr)
NZ (1) NZ714203A (fr)
PL (3) PL2989088T3 (fr)
PT (2) PT2989088T (fr)
RS (2) RS56717B1 (fr)
RU (3) RU2015146957A (fr)
SA (1) SA515370043B1 (fr)
SI (2) SI2989088T1 (fr)
TN (2) TN2015000445A1 (fr)
UA (1) UA115806C2 (fr)
WO (3) WO2014174062A1 (fr)
ZA (1) ZA201508545B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
TN2016000472A1 (en) 2014-04-25 2018-04-04 Pf Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer.
ES2764110T3 (es) * 2014-04-25 2020-06-02 Pf Medicament Conjugado anticuerpo-fármaco y su utilización para el tratamiento del cáncer
CA2954934C (fr) 2014-06-30 2023-09-26 Glykos Finland Oy Derive de medicament et conjugues
RU2018132749A (ru) * 2016-02-26 2020-03-26 Цзянсу Хэнжуй Медицин Ко., Лтд. Новый токсин и способ получения его промежуточного соединения
EP3438118B1 (fr) * 2016-03-29 2023-03-29 Toray Industries, Inc. Dérivé peptidique et son utilisation
CN105968038A (zh) * 2016-05-09 2016-09-28 湖北华世通生物医药科技有限公司 二肽类化合物的盐酸盐及其制备方法
CN106432318A (zh) * 2016-08-18 2017-02-22 重庆大学 一种芳炔前体的设计，合成，及在合成多取代芳烃的应用
CN107325033A (zh) * 2017-06-23 2017-11-07 华东师范大学 一种高立体选择性合成海兔毒素Dap片段的方法
NZ764948A (en) * 2017-11-30 2024-08-30 Ladrx Corp Albumin-binding prodrugs of auristatin e derivatives
CA3113378C (fr) 2018-09-27 2024-01-02 Pierre Fabre Medicament Lieurs a base de sulfomaleimide et conjugues correspondants
CN110724337B (zh) * 2019-10-16 2022-04-05 江苏德威新材料股份有限公司 一种硅烷交联型阻燃半导电聚烯烃护套材料及其制备方法和应用
KR20240051956A (ko) 2021-09-03 2024-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
TW202444737A (zh) * 2023-04-12 2024-11-16 大陸商榮昌生物製藥（煙臺）股份有限公司 一種甲基奧瑞他汀e化合物的製備及純化方法
WO2024245227A1 (fr) * 2023-06-02 2024-12-05 荣昌生物制药(烟台)股份有限公司 Procédé de préparation et de purification d'un intermédiaire de composé de méthyl auristatine e
CN118165066A (zh) * 2024-02-26 2024-06-11 复旦大学 一种含氟多肽及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767237A (en) * 1993-10-01 1998-06-16 Teikoku Hormone Mfg. Co., Ltd. Peptide derivatives
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2007008603A1 (fr) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Composes de monomethylvaline presentant des modifications de la chaine laterale de phenylalanine au niveau de l'extremite c
AU2009234267B2 (en) * 2008-04-11 2014-10-30 Seagen Inc. Detection and treatment of pancreatic, ovarian and other cancers
CA2754531A1 (fr) * 2009-03-06 2010-09-30 Seattle Genetics, Inc. Conjugues anticorps-medicament (adc) se liant aux proteines 24p4c12
US8722629B2 (en) * 2010-06-10 2014-05-13 Seattle Genetics, Inc. Auristatin derivatives and use thereof
JP5933562B2 (ja) * 2010-09-29 2016-06-15 シアトル ジェネティックス， インコーポレイテッド Ｎ−カルボキシアルキル−アウリスタチンおよびその使用
CA2813411C (fr) * 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Conjugues de polypeptides obtenus par genie biologique, et procede de fabrication correspondants au moyen de transglutaminase
ES2543888T3 (es) * 2011-03-16 2015-08-25 Seattle Genetics, Inc. N-carboxialquil-auristatinas y su utilización
WO2012143499A2 (fr) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Nouveaux conjugués liant-principe actif (adc) et leur utilisation
AU2012262560B2 (en) * 2011-05-27 2016-06-09 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
MX371526B (es) * 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
US10800856B2 (en) * 2012-06-07 2020-10-13 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
US10208123B2 (en) * 2012-06-19 2019-02-19 Ambrx, Inc. Anti-CD70 antibody drug conjugates
EP2934596A1 (fr) * 2012-12-21 2015-10-28 Glykos Finland Oy Conjugués constitués de molécules de charge utile et de lieurs
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
ES2764110T3 (es) * 2014-04-25 2020-06-02 Pf Medicament Conjugado anticuerpo-fármaco y su utilización para el tratamiento del cáncer

Also Published As

Publication number Publication date
US20200010414A1 (en) 2020-01-09
AU2014259429A1 (en) 2015-11-12
RU2015149527A (ru) 2017-05-29
HRP20181890T1 (hr) 2019-01-11
US20230002316A1 (en) 2023-01-05
KR102389167B1 (ko) 2022-04-20
MX2015014831A (es) 2016-08-03
AU2014259427A1 (en) 2015-11-19
CN105408318A (zh) 2016-03-16
BR112015026478A2 (pt) 2017-07-25
AU2014259431B2 (en) 2017-02-02
TN2015000439A1 (en) 2017-01-03
AU2014259431A1 (en) 2015-12-03
CA2910178A1 (fr) 2014-10-30
BR112015026565A2 (pt) 2017-07-25
HUE058167T2 (hu) 2022-07-28
WO2014174060A1 (fr) 2014-10-30
US20180222858A1 (en) 2018-08-09
EP3388427B1 (fr) 2022-01-19
SI2989088T1 (en) 2018-02-28
PL3388427T3 (pl) 2022-05-09
ZA201508545B (en) 2017-07-26
US20160068566A1 (en) 2016-03-10
KR20160003003A (ko) 2016-01-08
WO2014174062A1 (fr) 2014-10-30
KR102368136B1 (ko) 2022-02-25
CA3130994A1 (fr) 2014-10-30
AU2014259427B2 (en) 2018-04-05
NZ714203A (en) 2020-05-29
CY1120863T1 (el) 2019-12-11
UA115806C2 (uk) 2017-12-26
NO2989088T3 (fr) 2018-02-24
PT2989086T (pt) 2018-11-29
RU2662951C2 (ru) 2018-07-31
DK2989088T3 (en) 2017-12-18
ES2908224T3 (es) 2022-04-28
HRP20171977T1 (hr) 2018-02-09
EP2989088B1 (fr) 2017-09-27
HUE035180T2 (hu) 2018-05-02
DK2989086T3 (en) 2018-11-12
LT2989086T (lt) 2018-11-26
CA2909126A1 (fr) 2014-10-30
JP2016520041A (ja) 2016-07-11
HK1215867A1 (zh) 2016-09-23
PL2989086T3 (pl) 2019-02-28
WO2014174064A1 (fr) 2014-10-30
ES2693368T3 (es) 2018-12-11
KR20160003734A (ko) 2016-01-11
KR20210046871A (ko) 2021-04-28
MX2015014941A (es) 2016-03-07
KR101640361B1 (ko) 2016-07-15
CA2910176C (fr) 2021-11-09
BR112015026410A2 (pt) 2017-07-25
EP2989087A1 (fr) 2016-03-02
JP6017728B2 (ja) 2016-11-02
JP2016519114A (ja) 2016-06-30
US20160083420A1 (en) 2016-03-24
CA2910176A1 (fr) 2014-10-30
SI2989086T1 (sl) 2018-12-31
MA38583A1 (fr) 2018-07-31
FR3005051A1 (fr) 2014-10-31
BR112015026410B1 (pt) 2022-06-07
EP2989086A1 (fr) 2016-03-02
EP2989088A1 (fr) 2016-03-02
PL2989088T3 (pl) 2018-03-30
KR20160003735A (ko) 2016-01-11
TN2015000445A1 (en) 2017-04-06
US20160068567A1 (en) 2016-03-10
ES2654364T3 (es) 2018-02-13
RS58161B1 (sr) 2019-03-29
LT2989088T (lt) 2018-01-10
RS56717B1 (sr) 2018-03-30
SA515370043B1 (ar) 2018-01-24
US20210107868A1 (en) 2021-04-15
CN105377834B (zh) 2018-04-20
MY177702A (en) 2020-09-23
JP6606489B2 (ja) 2019-11-13
HK1215580A1 (zh) 2016-09-02
MX345126B (es) 2017-01-17
CN105377834A (zh) 2016-03-02
CN105143199A (zh) 2015-12-09
EP2989086B1 (fr) 2018-08-22
HUE040431T2 (hu) 2019-03-28
DK3388427T3 (da) 2022-03-07
CY1119677T1 (el) 2018-04-04
RU2015146957A (ru) 2017-05-31
EP3388427A1 (fr) 2018-10-17
RU2015147447A (ru) 2017-05-31
IL242184A (en) 2017-09-28
JP2016519115A (ja) 2016-06-30
PT2989088T (pt) 2018-01-03
MX2015014746A (es) 2016-03-04

Similar Documents

Publication Publication Date Title
MA38583A1 (fr) Dérivés de dolastatine 10 et d&#39;auristatines
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
BR112013002182A2 (pt) derivados de quinolina e inibidores de melk contendo os mesmos
MY180083A (en) Tetrahydropyrrolothiazine compounds
MA38050B1 (fr) Inhibiteurs de gdf-8
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201690911A1 (ru) Соединения диметилбензойной кислоты
RS54386B1 (en) ANTIVIRAL UNITS
RS54730B1 (sr) Inhibitori beta sekretaze
RS54207B1 (en) CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
MA38404A1 (fr) Nouveaux dérivés de pyridine
EA201592183A1 (ru) Ингибиторы bace
EA201690894A1 (ru) Феноксиэтилы
MA37686A1 (fr) Composés phénoxyéthyl pipéridine
MA37650A1 (fr) Forme amorphe d&#39;un composé pyrimidinyl-cyclopentane inhibiteur de akt, compositions et procédés de celle-ci
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
JOP20200030A1 (ar) مركب خماسي الحلقة
EA201690924A1 (ru) Фторфенилпиразольные соединения
MA20150280A2 (fr) Dérivés d&#39;aryléthynyle
EA201591819A1 (ru) Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10)
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека